Boston researchers exploring over-the-counter PrEP for HIV prevention
Add Axios as your preferred source to
see more of our stories on Google.

Illustration: Lindsey Bailey/Axios
Boston-area researchers are exploring whether PrEP, the HIV prevention medication, should be available over the counter.
Why it matters: The U.S. reported 32,100 estimated new HIV infections in 2021, per the Centers for Disease Control and Prevention.
The big picture: Health experts and advocates say the number of new infections should be far lower with the availability of prevention medication.
- They want to reduce the number of new infections to 3,000 by 2030.
- "PrEP is 99% effective or more in preventing HIV. It's safe, and it's low or no cost for nearly everyone," says Julia Marcus, a professor at Harvard Pilgrim Health Care Institute and Harvard Medical School.
- "At this point, we have no more excuses for why we are not ending new HIV infections in this country."
Zoom in: Marcus and Douglas Krakower, a fellow professor, received a $500,000 grant from the National Institutes of Health to conduct the research.
- They will survey gay and bisexual men, cisgender women and transgender women about whether they would want easy access to PrEP and why or why not.
- The research is modeled after studies conducted on whether to make birth control available over the counter.
Flashback: A yearslong "free the Pill" campaign involved studies on how making birth control available over the counter would affect the people who need it most but can't get to a doctor to obtain a prescription.
- Last July, the Food and Drug Administration approved the first over-the-counter oral contraceptive pill.
The PrEP research is happening out of the new LGBTQ Health Center of Excellence.
- The center, based at the Harvard Pilgrim Health Care Institute in partnership with Harvard T.H. Chan School of Public Health, launched last month.
- The center has 13 faculty members, a half-dozen postdoctoral fellows and various advisors, says Brittany Charlton, the center's founding director.
Spread the word.
